Research Analysts Offer Predictions for CATX FY2024 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a report issued on Monday, March 10th. Brookline Capital Management analyst K. Dolliver expects that the company will post earnings per share of ($0.88) for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Perspective Therapeutics’ Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.41) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.59) EPS and FY2026 earnings at ($2.04) EPS.

A number of other equities analysts also recently issued reports on CATX. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Royal Bank of Canada restated an “outperform” rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Oppenheimer dropped their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Scotiabank started coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target on the stock. Finally, Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $15.13.

Perspective Therapeutics Stock Performance

CATX stock opened at $2.50 on Wednesday. Perspective Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.05. The stock’s fifty day moving average price is $3.18 and its 200-day moving average price is $7.48.

Hedge Funds Weigh In On Perspective Therapeutics

Institutional investors have recently bought and sold shares of the stock. US Bancorp DE raised its holdings in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares during the period. Los Angeles Capital Management LLC bought a new stake in Perspective Therapeutics during the third quarter valued at about $153,000. WealthPlan Investment Management LLC bought a new stake in Perspective Therapeutics during the third quarter valued at about $4,530,000. Victory Capital Management Inc. raised its holdings in Perspective Therapeutics by 328.7% during the third quarter. Victory Capital Management Inc. now owns 50,460 shares of the company’s stock valued at $674,000 after acquiring an additional 38,690 shares during the period. Finally, CIBC Asset Management Inc bought a new stake in Perspective Therapeutics during the third quarter valued at about $259,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.